Psikiyatrik bakış açısı ile oral dizestezi

Yıl 2020, , 60 - 64, 30.09.2020

Işılay Manzak Saka , Demet Sağlam Aykut , Filiz Civil Arslan

https://doi.org/10.33204/mucosa.755275

Öz

Oral dizestezi, organik nedenlerle açıklanamayan karıncalanma, yabancı cisim hissi, tat değişiklikleri, ağrı ve
yanma gibi oral bölgelerde hissedilen anormal duyumları tanımlar. Oral dizestezinin bir varyantı olarak kabul
edilen yanan ağız sendromu, atipik odontalji ve persistan idiopatik yüz ağrısı orofasiyal bölgede ağrı hissi ve
anormal duyumla karakterize sendromlardır. Oral dizestezinin ve varyantlarının birçoğu idiopatik olup altta
yatan patogenez henüz net değildir. Litaratürde somatoform bozukluk başta olmak üzere birçok psikiyatrik
hastalıkla birlikteliğinin olabileceği gösterilmiştir. Psikiyatrik eş tanının sıklığına rağmen oral dizestezisi olan
hastalar, başta diş klinikleri olmak üzere psikiyatri dışı branşlara başvurmakta olup olası psikiyatrik tanılar
atlanabilmekte ve semptomların kronikleşmesine neden olabilmektedir. Bu açıdan oral dizestezi yakınmaları olan hastaların psikiyatrik açıdan da ele alınması gerekli görünmektedir.

Anahtar Kelimeler

oral dizestezi, Yanan Ağız Sendromu, Atipik Odontalji, psikiyatri, persistan idiopatik yüz ağrısı

Oral dysesthesia with a psychiatric perspective

Öz

Oral dysesthesia defines unusual sensation like inexplicable tingling sensation that could not be explained by
organic causes, foreign body feeling, taste changes, oral burn, and pain in the oral area. Burning mouth syndrome, atypic odontalgia, persistent idiopathic facial pain are considered a variant of oral dysesthesia and they are characterized by pain in the orofacial area and abnormal sensation. Many of the oral dysesthesia and variants are idiopathic and the underlying pathogenesis is not yet clear. It has been shown that it can coexist with many psychiatric diseases, especially somatoform disorder. Despite the frequency of psychiatric comorbidity, patients with oral dysesthesia apply to non-psychiatric branches, especially dental clinics, and possible psychiatric diagnoses may be skipped. This can cause symptoms to become chronic. In this regard, patients with oral dysesthesia and their complaints also need to be handled psychiatricly.

Anahtar Kelimeler

oral dysesthesia, psychiatry, Burning Mouth Syndrome, Atypic Odontalgia, Persistent İdiopathic Facial Pain

Kaynakça

• Headache classification subcommittee of the international headache society (IHS), The international classification of headache disorders. 3rd ed. Cephalalgia 2018;38:1-211.
• Sun A, Wu KM, Wang YP, Lin HP, Chen HM, Chiang CP. Burning mouth syndrome: a review and update. J Oral Pathol Med 2013;42:649-55.
• Melis M, Lobo SL, Ceneviz C, et al. Atypical odontalgia: A review of the literature. Headache 2003;43:1060-74.
• McMillan R, Forssell H, Buchanan JA, Glenny AM, Weldon JC, Zakrzewska JM. Interventions for the treatment of burning mouth syndrome. Cochrane Database Syst Rev 2016;11:CD002779.
• Baad-Hansen L. Atypical odontalgia-Pathophysiology and clinical management. J Oral Rehabil 2008;35:1- 11.
• Yilmaz Z, Renton T, Yiangou Y, et al. Burning mouth syndrome as a trigeminal small fibre neuropathy: Increased heat and capsaicin receptor TRPV1 in nerve fibres correlates with pain score. J Clin Neurosci 2007; 14:864-71.
• Benarroch EE. Central neuron-glia interactions and neuropathic pain: Overview of recent concepts and clinical implications. Neurology 2010;75:273-8.
• Boras VV, Brailo V, Lukac J, Kordic D, Blazic Potocki Z. Salivary interleukin-6 and tumor necrosis factoralpha in patients with burning mouth syndrome. Oral Dis 2006;12:353-5.
• Chen Q, Xia J, Lin M, Zhou H, Li B. Serum interleukin-6 in patients with burning mouth syndrome and relationship with depression and perceived pain. Mediators Inflamm 2007;45327.
• Pekiner FN, Demirel GY, Gumru B, Ozbayrak S. Serum cytokine and T regulatory cell levels in patients with burning mouth syndrome. J Oral Pathol Med 2008;37:528-34.
• Simcic D, Pezelj-Ribaric S, Grzic R, Horvat J, Brumini G, MuhvicUrek M. Detection of salivary interleukin 2 and interleukin 6 in patients with burning mouth syndrome. Mediators Inflamm 2006;54632.
• Suh KI, Kim YK, Kho HS. Salivary levels of IL-1beta, IL-6, IL-8, and TNF-alpha in patients with burning mouth syndrome. Arch Oral Biol 2009;54:797-802.
• Guimaraes AL, de Sa AR, Victoria JM, de Fatima Correia-Silva J, Gomez MV, Gomez RS. Interleukin-1beta and serotonin transporter gene polymorphisms in burning mouth syndrome patients. J Pain 2006;7:654-8.
• Kim MJ, Kim J, Chang JY, Kim YY, Kho HS.Polymorphisms of interleukin-1β and MUC7 genes in burning mouth syndrome. Clin Oral Investig 2017;21:949-55.
• Abbadie C, Bhangoo S, De Koninck Y, Malcangio M, MelikParsadaniantz S, White FA. Chemokines and pain mechanisms. Brain Res Rev 2009;60:15-134.
• Barry A, O’Halloran KD, McKenna JP, McCreary C, Downer EJ. Plasma IL-8 signature correlates with pain and depressive symptomatology in patients with burning mouth syndrome: Results from a pilot study. J Oral Pathol Med 2018;47:158-65.
• Pezelj-Ribaric S, Kqiku L, Brumini G, et al. Proinflammatory cytokine levels in saliva in patients with burning mouth syndrome before and after treatment with lowlevel laser therapy. Lasers Med Sci 2013;28:297-301.
• Umemura E, Tokura T, Ito M, et al. Oral medicine psychiatric liaison clinic: study of 1202 patients attending over an 18-year period. Int J Oral Maxillofac Surg 2019;48:644-50.
• Wardrop RW, Hailes J, Burger H, Reade PC. Oral discomfort at menopause. Oral Surg Oral Med Oral Pathol 1989;67:535-40.
• Nicholson M, Wilkinson G, Field E, Longman L, Fitzgerald B. A pilot study: stability of psychiatric diagnoses over 6 months in burning mouth syndrome. J Psychosom Res 2000;49:1-2.
• de Souza FT, Teixeira AL, Amaral TM, et al. Psychiatric disorders in burning mouth syndrome. J Psychosom Res 2012;72:142-6.
• Tokura T, Kimura H, Ito M, et al. Temperament and character profiles of patients with burning mouth syndrome. J Psychosom Res 2015;78:495-8.
• Turner JA, Dworkin SF. Screening for psychosocial risk factors in patients with chronic orofacial pain: recent advances. J Am Dent Assoc 2004;135:1119-25.
• Uezato A, Toyofuku A, Umezaki Y, Nishikawa T. Oral dysesthesia associated with autistic traits: a retrospective chart review. Eur J Oral Sci 2019;00:1-4.
• Nagashima W, Kimura H, Ito M, et al. Effectiveness of duloxetine for the treatment of chronic nonorganic orofacial pain. Clin Neuropharmacol 2012;35:273-7.
• Kobayashi Y, Nagashima W, Tokura T, et al. Duloxetine plasma concentrations and its effectiveness in the treatment of nonorganic chronic pain in the orofacial region. Clinical Neuropharmacology 2017;40:163-8.
• Miyauchi T, Tokura T, Kimura H, et al. Effect of antidepressant treatment on plasma levels of neuroinflammation-associated molecules in patients with somatic symptom disorder with predominant pain around the orofacial region, Hum Psychopharmacol Clin Exp 2019;34:e2698.
• Sharifabadi AR, Hassanshahi G, Ghalebi SR, et al. All eotaxins CCL11, CCL24 and CCL26 are increased but to various extents in pulmonary tuberculosis patients. Clin Lab 2014;60:93-7.
• Chalan P, Bijzet J, van den Berg A, et al. Analysis of serum immune markers in seropositive and seronegative rheumatoid arthritis and in high risk seropositive arthralgia patients. Sci Rep 2016;6:26021.
• Backryd E, Lind AL, Thulin M, Larsson A, Gerdle B, Gordh T. High levels of cerebrospinal fluid chemokines point to the presence of neuroinflammation in peripheral neuropathic pain: A cross-sectional study of 2 cohorts of patients compared with healthy controls. Pain 2017;158:2487-95.
• Makker PG, Duffy SS, Lees JG, et al. Characterisation of immune and neuroinflammatory changes associated with chemotherapy-induced peripheral neuropathy. PLoS One 2017;12:e0170814.
• Kimura H, Yoshida K, Ito M, et al. Plasma levels of milnacipran and its effectivenessfor the treatment of chronic pain in the orofacial region. Hum Psychopharmacol 2012;27:322-8.
• Ito M, Kimura H, Yoshida K, Kimura Y, Ozaki N, Kurita K. Effectiveness of milnacipran for the treatment of chronic pain in the orofacial region. Clin Neuropharmacol 2010;33:79-83.